NASDAQ · BCAX

Bicara Therapeutics Inc.

$27.02 -$0.71 (-2.56%) 1D After hours
Charting by TradingView

Key Metrics

$1.82B
Market cap
—
P/E · TTM
—
Revenue · TTM
−$157.32M
Net income
EPS · TTM $-2.89
Dividend yield —
Free cash flow −$116.58M
Beta · 1Y 1.14
EBITDA · TTM −$156.99M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 29
    The stock moved +9.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 29

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.82B
Enterprise value—
Shares outstanding65.7M
52-wk range$9.57 – $30.99
Avg volume · 20D584.4K
Net cash —
Book value / share$9.44
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Bicara Therapeutics Inc.
IPO dateSep 13, 2024
Employees103

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net —
FCF —
ROE / ROIC -31.3% · 609.9%

Financial Health

Current ratio13.85
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$505.58M

Cash Flow · TTM

Operating CF −$116.24M
Capex −$340.00K
Free cash flow −$116.58M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings